WO2002066492A3 - Human adrenomedullin-specific antibody, pharmaceutical composition containing same, therapeutic uses thereof - Google Patents

Human adrenomedullin-specific antibody, pharmaceutical composition containing same, therapeutic uses thereof Download PDF

Info

Publication number
WO2002066492A3
WO2002066492A3 PCT/FR2002/000638 FR0200638W WO02066492A3 WO 2002066492 A3 WO2002066492 A3 WO 2002066492A3 FR 0200638 W FR0200638 W FR 0200638W WO 02066492 A3 WO02066492 A3 WO 02066492A3
Authority
WO
WIPO (PCT)
Prior art keywords
specific antibody
therapeutic uses
pharmaceutical composition
composition containing
containing same
Prior art date
Application number
PCT/FR2002/000638
Other languages
French (fr)
Other versions
WO2002066492A2 (en
Inventor
Pierre Marie Martin
L Houcine Ouafik
Original Assignee
Sanofi Synthelabo
Assist Publ Hopitaux De Paris
Pierre Marie Martin
L Houcine Ouafik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo, Assist Publ Hopitaux De Paris, Pierre Marie Martin, L Houcine Ouafik filed Critical Sanofi Synthelabo
Priority to AU2002238673A priority Critical patent/AU2002238673A1/en
Publication of WO2002066492A2 publication Critical patent/WO2002066492A2/en
Publication of WO2002066492A3 publication Critical patent/WO2002066492A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration

Abstract

The invention concerns an adrenomedullin-specific antibody, for use in cancer treatment. The invention also concerns pharmaceutical compositions containing an anti-adrenomedullin antibody and their therapeutic uses.
PCT/FR2002/000638 2001-02-20 2002-02-20 Human adrenomedullin-specific antibody, pharmaceutical composition containing same, therapeutic uses thereof WO2002066492A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002238673A AU2002238673A1 (en) 2001-02-20 2002-02-20 Human adrenomedullin-specific antibody, pharmaceutical composition containing same, therapeutic uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0102291A FR2821080B1 (en) 2001-02-20 2001-02-20 SPECIFIC ANTIBODIES TO HUMAN ADRENOMEDULLINE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ITS THERAPEUTIC APPLICATIONS
FR01/02291 2001-02-20

Publications (2)

Publication Number Publication Date
WO2002066492A2 WO2002066492A2 (en) 2002-08-29
WO2002066492A3 true WO2002066492A3 (en) 2003-02-27

Family

ID=8860234

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2002/000638 WO2002066492A2 (en) 2001-02-20 2002-02-20 Human adrenomedullin-specific antibody, pharmaceutical composition containing same, therapeutic uses thereof

Country Status (3)

Country Link
AU (1) AU2002238673A1 (en)
FR (1) FR2821080B1 (en)
WO (1) WO2002066492A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003288914A1 (en) * 2002-09-30 2004-04-19 Bayer Pharmaceuticals Corporation Methods for prediction and prognosis of cancer, and monitoring cancer therapy
JO3382B1 (en) 2008-12-23 2019-03-13 Amgen Inc Human cgrp receptor binding antibodies
FR2964103B1 (en) 2010-08-30 2018-11-23 Universite D'aix-Marseille ANTIBODIES BINDING TO ADRENOMEDULLINE AND RECEPTORS OF ADRENOMEDULLINE AND THEIR USES AS A MEDICINAL PRODUCT
EP2589963A1 (en) * 2011-11-04 2013-05-08 Université de Provence (Aix-Marseille 1) Diagnostic and treatment of an androgen-independent prostate cancer
MX2017003247A (en) 2014-09-15 2017-11-30 Amgen Inc Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof.
JOP20200116A1 (en) 2015-04-24 2017-06-16 Amgen Inc Methods for treating or preventing migraine headache
EA202092335A1 (en) 2018-04-02 2021-01-22 Эмджен Инк. COMPOSITIONS BASED ON ERENUMAB AND WAYS OF THEIR APPLICATION

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0622458A2 (en) * 1993-04-26 1994-11-02 Shionogi & Co., Ltd. Adrenomedullin
WO1997007214A1 (en) * 1995-08-18 1997-02-27 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0622458A2 (en) * 1993-04-26 1994-11-02 Shionogi & Co., Ltd. Adrenomedullin
WO1997007214A1 (en) * 1995-08-18 1997-02-27 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BORGSTROM P ET AL: "COMPLETE INHIBITION OF ANGIOGENESIS AND GROWTH OF MICROTUMORS BY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR NEUTRALIZING ANTIBODY: NOVEL CONCEPTS OF ANGIOSTATIC THERAPY FROM INTRAVITAL VIDEOMICROSCOPY", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 56, 1 September 1996 (1996-09-01), pages 4032 - 4039, XP002918735, ISSN: 0008-5472 *
MILLER MAE JEAN ET AL: "Adrenomedullin expression in human tumor cell lines: Its potential role as an autocrine growth factor.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 38, 1996, pages 23345 - 23351, XP002184272, ISSN: 0021-9258 *
ZHAO YUAN ET AL: "PCR display identifies tamoxifen induction of the novel angiogenic factor adrenomedullin by a non estrogenic mechanism in the human endometrium.", ONCOGENE, vol. 16, no. 3, 22 January 1998 (1998-01-22), pages 409 - 415, XP001113057, ISSN: 0950-9232 *

Also Published As

Publication number Publication date
FR2821080B1 (en) 2003-12-19
FR2821080A1 (en) 2002-08-23
AU2002238673A1 (en) 2002-09-04
WO2002066492A2 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2004058837A3 (en) Ampholytic copolymer and use thereof
HUP0402566A3 (en) C-5 modified indazolylamino pyrrolotriazines, their use and pharmaceutical compositions containing them
HUP0400231A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
WO2001070275A3 (en) Polyglutamic acid-camptothecin conjugates and methods of preparation
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
WO2003053383A3 (en) Cosmetic use of at least a hydrophobin for treating keratinous materials
WO2003066661A3 (en) Human dr4 antibodies and uses thereof
TR200100054T2 (en) Paroxetine methanesulfonate
AU2386201A (en) Substituted sapogenins and their use
PL1654253T3 (en) Substituted 3-pyrrolidin-indole derivatives
ZA200205191B (en) LIV-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer.
AU2002303219A1 (en) Compositions and methods for the therapy and diagnosis of cancer
MXPA03010684A (en) Peptides and the use thereof in darkening the skin.
AU2001245295A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
HUP0400153A2 (en) Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment
WO2002066492A3 (en) Human adrenomedullin-specific antibody, pharmaceutical composition containing same, therapeutic uses thereof
HUP0303469A3 (en) Phtalazinon-derivatives, their use and pharmaceutical compositions containing them
AU2001238493A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
HUP0401644A3 (en) Aminobenzoephenones, pharmaceutical compositions containing them and use thereof
AU2002337713A1 (en) Pharmaceutical compositions and methods for treating cancer
IL158587A0 (en) Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof
AU2003206144A1 (en) Pharmaceutical composition for cancer treatment containing p43 protein and paclitaxel, therapy method using the same and use thereof
AU2001245939A1 (en) Compositions and methods for the identification, assessment, prevention, and therapy of human cancers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP